You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Treatment outcomes of patients with salivary gland adenoid cystic carcinoma bearing adverse pathological risk factors in the propensity score-matched cohort, treatment with PORT versus POCRT

From: Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but Not overall survival in patients with salivary gland adenoid cystic carcinoma—a propensity score matched study

  LRC DMFS DFS OS ORPFS
Variable N 5-yr 8-yr P 5-yr 8-yr P 5-yr 8-yr P 5-yr 8-yr P 5-yr 8-yr P
Stage III-IV
 PORT 15 70.6 49.4 .040 47.7 47.7 .601 40.9 32.7 .963 77.8 60.0 .705 62.2 43.6 .017
 POCRT 19 94.4 94.4   43.8 29.2   43.8 29.2   75.9 60.7   92.9 92.9  
Margins < 1 mm
 PORT 26 73.7 60.5 .011 59.0 59.0 .669 54.3 48.3 .972 86.2 74.1 .894 81.6 68.2 .050
 POCRT 28 96.4 96.4   54.5 37.4   54.5 37.4   79.8 71.8   95.5 95.5  
Perineural invasion
 PORT 24 73.1 58.6 .013 54.5 54.5 .849 49.9 43.7 .857 81.6 69.2 .792 77.2 63.4 .035
 POCRT 27 96.2 96.2   52.1 41.7   52.1 41.7   77.2 68.7   95.0 95.0  
Bone invasion
 PORT 8 87.5 52.5 .425 45.0 45.0 .652 45.0 30.0 .851 72.9 72.9 .220 72.9 43.8 .260
 POCRT 11 90.0 90.0   50.5 50.5   50.5 50.5   52.6 52.6   83.3 83.3  
Muscle invasion
 PORT 11 57.3 43.0 .240 54.5 54.5 .260 43.0 28.6 .608 77.9 48.7 .772 54.5 40.9 .214
 POCRT 7 85.7 85.7   19.0 19.0   19.0 19.0   80.0 80.0   83.3 83.3  
  1. Data for survival estimates are expressed as percentages
  2. Abbreviations: PORT postoperative radiotherapy, POCRT postoperative chemoradiotherapy, LRC locoregional control, DMFS distant metastasis-free survival, DFS disease-free survival, OS overall survival, ORPFS opioid-requiring pain-free survival